Lv1
80 积分 2024-12-31 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
21小时前
待确认
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
21小时前
已完结
Comparison of validity of standard nonclinical group size selection versus standard clinical group sizes for nonhuman primate QTc prolongation evaluation
2个月前
已完结
Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review
2个月前
已完结
Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology
2个月前
已完结
A comprehensive review of 20 years of progress in nonclinical QT evaluation and proarrhythmic assessment
2个月前
已完结
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL
2个月前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
3个月前
已完结
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
3个月前
已完结
皖公网安备34019202002308
